NewAmsterdam Pharma (NAMS) Return on Sales (2023 - 2026)

NewAmsterdam Pharma has disclosed Return on Sales across 4 years of filings, most recently posting 0.16% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.16%, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.09% (down 8.0% YoY), and the FY2025 annual result was 0.09%, down 7.0% from the prior year.
• Return on Sales came in at 0.16% for Q1 2026 at NewAmsterdam Pharma, up from 23.41% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q4 2024 to a low of 23.41% in Q4 2025.
• The 4-year median for Return on Sales is 0.16% (2023), against an average of 2.28%.
• Across the five-year window, Return on Sales soared 65 bps in 2024 and slumped 2345 bps in 2025, its largest moves.
• NewAmsterdam Pharma's Return on Sales stood at 0.62% in 2023, then soared by 106 bps to 0.04% in 2024, then plunged by 62328 bps to 23.41% in 2025, then surged by 99 bps to 0.16% in 2026.
• The last three Return on Sales figures came in at 0.16% (Q1 2026), 23.41% (Q4 2025), and 2.07% (Q3 2025), per Business Quant data.